Organization | Southern California Institute for Research and Education

Southern California Institute for Research and Education Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2013

NCT01890772

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (4)

interferon alpha-2b (Intron-A) (1 trial)

ribavirin (virazole) (2 trials)

telaprevir (incivek) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (4)

filgrastim (neupogen) (1 trial)

mycophenolate (myfortic) (1 trial)

prednisone (meticorten) (1 trial)

rilonacept (arcalyst) (1 trial)

Drugs in Other Trials (3)

beclabuvir (1 trial)

daclatasvir (daklinza) (1 trial)

sunvepra (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis, Alcoholic (Phase 2)

Hepatitis C (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 11